22.85
0.97 (4.43%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Jade Biosciences, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 33.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Remedium Capital Partners, Llc | 31 Dec 2025 | 1,577,750 |
| Versant Venture Management, Llc | 31 Dec 2025 | 1,525,820 |
| Avidity Partners Management Lp | 31 Dec 2025 | 1,400,708 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (Wedbush, 5.03%) | Buy |
| Median | 23.50 (2.85%) | |
| Low | 23.00 (Guggenheim, 0.66%) | Buy |
| Average | 23.50 (2.85%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 14.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 11 Mar 2026 | 23.00 (0.66%) | Buy | 14.02 |
| Wedbush | 09 Mar 2026 | 24.00 (5.03%) | Buy | 14.43 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |